Overview Phase IIa Clinical Trial of Hepalatide in CHD Patients Status: Not yet recruiting Trial end date: 2024-03-31 Target enrollment: Participant gender: Summary A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D Phase: Phase 2 Details Lead Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.